Cyclacel Pharmaceuticals, Inc. (CYCC):企業概要、財務及び戦略的SWOT分析

◆英語タイトル:Cyclacel Pharmaceuticals, Inc. (CYCC) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH37480FSA
◆発行会社(調査会社):GlobalData
◆発行日:2015年1月9日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD300 ⇒換算¥33,900見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD600 ⇒換算¥67,800見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD900 ⇒換算¥101,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary

Cyclacel Pharmaceuticals, Inc. (Cyclacel Pharmaceuticals) is a pharmaceutical company. The company develops oral therapies for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, and CYC116. Cyclacel Pharmaceuticals’ sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia; Seliciclib is an orally available, cyclin dependent kinase inhibitor; and CYC116 is an orally-active inhibitor of Aurora kinases A and B, and VEGFR2. It offers products for anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company has agreement with the U.S. Food and Drug Administration. Cyclacel Pharmaceuticals is headquartered in Berkeley Heights, New Jersey, the US.

Cyclacel Pharmaceuticals, Inc. Key Recent Developments

Nov 12, 2013: Cyclacel Reports Third Quarter 2013 Financial Results
Nov 06, 2013: Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results
Aug 14, 2013: Cyclacel Reports Second Quarter 2013 Financial Results
Aug 08, 2013: Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2013 Financial Results
Jul 05, 2013: Cyclacel Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2013

This comprehensive SWOT profile of Cyclacel Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Cyclacel Pharmaceuticals, Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Cyclacel Pharmaceuticals, Inc. – Key Information
Cyclacel Pharmaceuticals, Inc. – Overview
Cyclacel Pharmaceuticals, Inc. – Key Employees
Cyclacel Pharmaceuticals, Inc. – Key Employee Biographies
Cyclacel Pharmaceuticals, Inc. – Key Operational Heads
Cyclacel Pharmaceuticals, Inc. – Major Products and Services
Cyclacel Pharmaceuticals, Inc. – History
Cyclacel Pharmaceuticals, Inc. – Company Statement
Cyclacel Pharmaceuticals, Inc. – Locations And Subsidiaries
Cyclacel Pharmaceuticals, Inc. – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Cyclacel Pharmaceuticals, Inc. – Business Description
Cyclacel Pharmaceuticals, Inc. – Corporate Strategy
Cyclacel Pharmaceuticals, Inc. – SWOT Analysis
SWOT Analysis – Overview
Cyclacel Pharmaceuticals, Inc. – Strengths
Cyclacel Pharmaceuticals, Inc. – Weaknesses
Cyclacel Pharmaceuticals, Inc. – Opportunities
Cyclacel Pharmaceuticals, Inc. – Threats
Cyclacel Pharmaceuticals, Inc. – Key Competitors

Section 3 – Company Financial Performance Charts

Cyclacel Pharmaceuticals, Inc. – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Cyclacel Pharmaceuticals, Inc., Key Information
Cyclacel Pharmaceuticals, Inc., Key Ratios
Cyclacel Pharmaceuticals, Inc., Share Data
Cyclacel Pharmaceuticals, Inc., Major Products and Services
Cyclacel Pharmaceuticals, Inc., History
Cyclacel Pharmaceuticals, Inc., Key Employees
Cyclacel Pharmaceuticals, Inc., Key Employee Biographies
Cyclacel Pharmaceuticals, Inc., Key Operational Heads
Cyclacel Pharmaceuticals, Inc., Other Locations
Cyclacel Pharmaceuticals, Inc., Subsidiaries
Cyclacel Pharmaceuticals, Inc., Key Manufacturing facilities
Cyclacel Pharmaceuticals, Inc., Key Competitors
Cyclacel Pharmaceuticals, Inc., SWOT Analysis
Cyclacel Pharmaceuticals, Inc., Ratios based on current share price
Cyclacel Pharmaceuticals, Inc., Annual Ratios
Cyclacel Pharmaceuticals, Inc., Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Cyclacel Pharmaceuticals, Inc., Performance Chart
Cyclacel Pharmaceuticals, Inc., Ratio Charts

★海外企業調査レポート[Cyclacel Pharmaceuticals, Inc. (CYCC):企業概要、財務及び戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • United Overseas Bank Limited:企業の戦略・SWOT・財務分析
    SummaryUnited Overseas Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company …
  • Archimedes Pharma Limited:(医療機器分野)企業M&A及び提携動向
    Summary Archimedes Pharma Limited (APL) is a specialty pharmaceutical company. The company markets products for pain, oncology and critical care domains. Its products include PecFent (fentanyl pectin nasal spray) in EU, Gliadel implant (carmustine), Zomorph capsule (morphine sulphate), Oramorph oral …
  • Dion Global Solutions Limited (526927):企業の財務及び戦略的SWOT分析
    Summary Dion Global Solutions Limited (Dion Global) is a software solutions company that provides cutting-edge solutions and services for the international financial markets. The company product include trading, settlement, wealth management, governance, risk, compliance, messaging, workflow, analyt …
  • Peat Resources Limited (PET):企業財務及び戦略的SWOT分析
    Summary Peat Resources Limited (Peat Resources) is an oil and gas company that explores, develops and produces peat fuels. The company’s peat is a biomass that is used for electricity generations. Its peat is a source material for value-added biocarbon products such as activated carbon that are used …
  • SMandA, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' SM&A, Inc. Mergers and Acquisit …
  • Nutreco N.V.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Nutreco N.V. Mergers and Acquis …
  • ITT Corporation:企業の戦略・SWOT・財務分析
    SummaryITT Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Finding …
  • Fortress Investment Group LLC:企業の戦略・SWOT・財務分析
    SummaryFortress Investment Group LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the compan …
  • Waste Services, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Waste Services, Inc. Mergers an …
  • DiagnoCure Inc. (CUR):企業の財務及び戦略的SWOT分析
    Summary DiagnoCure Inc. (DiagnoCure) is a medical device company that provides diagnostic test solutions. The company develops and commercializes molecular diagnostic tests for the detection and management of cancer. Its products are used in gene expression and copy number variation (CNV) analysis, …
  • Amaru, Inc. (AMRU):企業の財務及び戦略的SWOT分析
    Summary Amaru, Inc. (Amaru) is Telecommunication Company that is in the business of broadbands entertainment. The company on demand streams via computers, television sets, PDAs (Personal Digital Assistant) and 3G hand phone. It offers services such as advertising and channel sponsorship, online subs …
  • Jastec Co., Ltd. (9717):企業財務及び戦略的SWOT分析
    Summary Jastec Co., Ltd. (Jastec) is a technology company that offers custom software development and system integration solutions. The company’s products include business service systems, middle-ware, operating system, process rationalization systems, programming language, and products for enterpri …
  • Dyax Corp.:企業のM&A・提携・投資分析
    Dyax Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dyax Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • United National Breweries (SA) (Pty) Limited:企業の戦略・SWOT・財務分析
    SummaryUnited National Breweries (SA) (Pty) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ vie …
  • Gujarat NRE Coke Limited (GUJNRECOKE):企業財務及び戦略的SWOT分析
    Summary Gujarat NRE Coke Limited (GNCL) is a coke manufacturer that provides low ash metallurgical coke. The company's products include met coke, electric power and TMT bars. It generates electricity from wind power projects and cogeneration power plants. GNCL offers services such as recycling of st …
  • USG Corporation:企業の戦略・SWOT・財務分析
    SummaryUSG Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Finding …
  • Ellex Medical Lasers Limited (ELX):企業のM&A・提携動向(医療機器分野)
    Summary Ellex Medical Lasers Limited (Ellex) is a medical technology company. It develops, manufactures, services, and distributes a comprehensive range of medical equipment for use in ophthalmic procedures. The company also offers a range of third-party medical devices and technologies. Ellex’s pro …
  • AntriaBio, Inc. (ANTB):企業の財務及び戦略的SWOT分析
    Summary AntriaBio, Inc. (AntriaBio), formerly Fits My Style is a bio pharmaceutical company that offers novel extended release therapies and manufacturing capabilities with molecules to significantly improve standards of care. The company offers diabetes product such as AB101 for type 1 and type 2 d …
  • Evonik Industries AG (EVK):企業のM&A・提携動向(発電分野)
    Summary Evonik Industries AG (Evonik) is a specialty chemical company. Its activities focus on high-growth megatrends, especially health, nutrition, resource efficiency and globalization. The company offers specialty chemicals, healthcare products, polymer materials and intermediates. Its products f …
  • Kesko Oyjの企業概要及び財務/SWOT分析
    Kesko Oyj Fundamental Company Report provides a complete overview of the company’s affairs. The report includes financial and SWOT information, industry analysis, opinions, estimates, Kesko Oyj annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆